Course curriculum

  • 1

    General Information

    • Learning Objectives

    • Course overview (Faculty, Structure, Assessment, Certificate)
  • 2

    Session 1 – Treatment of HF – a general approach

    • Modulating the renin angiotensin system | P. van der Meer

    • Redefining β-blocker response in HF | M. Flather

    • New aspects of mineralocorticoid receptor antagonists in HF | B. Pitt

    • Sodium-glucose cotransporter-2 inhibitors | P. Jhund

    • Tips and tricks blocking the renin angiotensin system - cases | P. van der Meer

    • List of Publications - Session 1

    • Quiz Session 1
  • 3

    Session 2 – Renal Injury and HF / Cardiorenal syndrome

    • Pathophysiology of cardio-renal interactions | W. Mullens

    • Renal function & SGLT-2 inhibitors | C. Wanner

    • Does SGLT1 add anything to SGLT2 inhibition in HF? | B. Pitt

    • Hyperkalemia, MRAs & potassium binders | F. Zannad

    • Tips and tricks balancing potassium levels - cases | K. McCafferty

    • Case studies of SGLT-2 inhibitors and renal dysfunction | C. Wanner

    • List of Publications - Session 2

    • Quiz Session 2
  • 4

    Session 3 – Treatment: the old and the new & Clinical trials and drug development

    • Diuretics in HF: when and how much? | W. Mullens

    • Digitalis in HF: outdated or a must? | J. Cleland

    • Vericiguat | B. Pieske

    • Omecamtiv mecarbil | J. Cleland

    • Tips and tricks using diuretics – cases | H.-P. Brunner -La Rocca

    • Heart rate control: Betablockers vs. Ivabradine – cases | H. O. Savage

    • How to read and interpret RCTs | J. Gregson

    • Challenges to design device trials | J. Cleland

    • Registry-based trials in HF | L. Lund

    • List of Publications - Session 3

    • Quiz Session 3
  • 5

    Session 4 –Atrial fibrillation and chronic HF

    • 2020 ESC Guidelines on atrial fibrillation | C. Blomström-Lundqvist

    • Catheter ablation in AF and HF | G. Hindricks

    • Prevention of embolic events in HF with and without AF | G. Lip

    • Live in-a-box: AF ablation | S. Haldar

    • Mobile health technologies in AF and HF | D. Kotecha

    • Anticoagulation in HF: which drug for which patient | G. Lip

    • List of Publications - Session 4

    • Quiz Session 4
  • 6

    Session 5 – Arrhythmias in chronic HF & CRT in chronic HF

    • The dark side of drugs: proarrhythmia, interactions and CHF | A. J. Camm

    • Ventricular tachycardias and ventricular fibrillation in HF | P. Della Bella

    • Arrhythmia management in GUCH patients | S. Ernst

    • Regular atrial tachycardia and the role of tachymyopathy in heart failure patients | S. Ernst

    • Cardiac anatomy and CRT: lessons from the implanter | G. Hindricks

    • Current guidelines and indications for CRT and ICD | M. B. Kronborg

    • When switching from CRT-P to CRT-D? | C. Linde

    • Live in-a-box: CRT-D | S. Haldar

    • Selecting CRT-P vs. CRT-D: patient cases | C. Linde

    • List of Publications - Session 5

    • Quiz Session 5
  • 7

    SESSION 6 – Myocarditis, Cardiac Sarcoidosis and Covid-19 & Regenerative Medicine and Heart Failure

    • Myocarditis: causes, clinical presentation and management | C. Tschöpe

    • Cardiac Sarcoidosis: diagnosis and management | R. Sharma

    • Covid-19 and myocarditis |B. Heidecker

    • Covid-19 and heart failure | M. Senni

    • Cardiovascular repair and regeneration – an update | U. Landmesser

    • RNA-based therapeutics for cardiac diseases | T. Thum

    • Gene therapy in cardiomyopathy: is it ready for prime time | B. Meder

    • List of Publications - Session 6

    • Quiz Session 6
  • 8

    Module Evaluation

    • Course Evaluation Questionnaire
Please note that accreditation and certification for Module 3 - 2nd Edition is possible until 15.07.2024